Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.
Allergy(2023)
摘要
This trial demonstrated a clinically relevant and statistically significant efficacy response to PQ Grass. Unprecedented effect sizes were reached for grass allergy of up to ≈40% compared to placebo for CSMS after only six PQ Grass injections. Both PQ Grass regimens were considered equally safe and well-tolerated. Based on enhanced efficacy profile extended regime will be progressed to the pivotal Phase III trial.
更多查看译文
关键词
allergic rhinoconjunctivitis, grass pollen allergy, short-course treatment, subcutaneous immunotherapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要